

Insurance - Life | Hong Kong | March 14, 2022



Hong Kong

ADD (no change)

Consensus ratings*: B	uy37 Hold3 Sell0
-----------------------	------------------

Current price:	HK\$77.25
Target price:	HK\$101.0
Previoustarget:	HK\$107.0
Up/downside:	30.7%
CGS-CIMB / Consensus:	-5.6%
Reuters:	1299.HK
Bloomberg:	1299 HK
Market cap:	US\$119,417m
	HK\$934,520m
Average daily turnover:	US\$230.0m
	HK\$1,794m
Current shares o/s:	12,097m
Free float:	100.0%
*Source: Bloomberg	

Key changes in this note

FY22F EPS cut by 10.2%.

FY23F EPS cut by 5.4%.

FY24F EPS cut by 5.8%



Absolute (%)	-11.5	-5.6	-23.8
Relative (%)	6	8.8	6.3
Major shareholders JPMorgan Chase & C	% held 9.4		
The Bankof New Yor		9.1	
The Capital Group Co	nc.	5.2	

AIA Group

Ending an 11-year wait

- An 11-year wait has ended, with a share buyback of up to US\$10bn, the first since its 2010 IPO. FY21 free surplus was US\$25bn after adoption of RBC.
- VONB was impressive, with FY21 up 22% yoy and 4Q21 up 26% yoy, driven primarily by HK and, to a lesser extent, Thailand.
- 1H22F remains a key challenge, due to a high base in China in 1Q22F and given Omicron-related uncertainty in HK in 1H22F.
- Reiterate Add rating. AIA remains our top pick in the sector. Our lower TP of HK\$101 is due to lower FY22F-24F VONB estimates.

Capital management a surprise; VONB, EV and net profit beat

The key standout of the FY21 results was the US\$10bn share buyback programme and 22% growth yoy in value of new business (VONB; 4% above consensus and 3% above our estimate). FY21 net profit also beat our forecast by 27%, driven by realised gains on bonds. FY21 embedded value (EV) beat our forecast by 6% (Fig 1).

What we liked about the FY21 results

i) 4Q21 VONB was up 26% yoy (or 28% yoy on a constant exchange rate [CER] basis), a marked improvement from 3Q21's 4% yoy (2% yoy on a CER basis; Fig 3), driven by HK and Thailand, across both agency and bancassurance; ii) a share buyback programme of up to US\$10bn over three years. This is significant as AIA has historically been unwilling to return its sizeable excess capital to shareholders since its 2010 IPO. Its FY21 Group Local Capital Summation Method (LCSM) ratio was 399%, with free surplus of US\$25bn after adoption of HK's new risk-based capital (RBC) regime (US\$17bn before adoption). FY21 underlying free surplus generation was US\$6.5bn, up 8% yoy; iii) 74% VONB grow th yoy on a like-for-like basis in FY21 for Tianjin, Shijiazhuang and Sichuan; iv) China active agent numbers returned to grow th hoh in 2H21 (Fig 9); v) Macau continues to record strong grow th in mainland Chinese visitors (MCV) buying insurance, with annualised new premiums for this segment more than doubling in FY21, which is consistent with our bullish view of this segment (*A welcome diversion*, dated 6 Jan 2022).

What we did not like about the FY21 results

i) A marked slow down of VONB grow th in most regions apart from HK in 2H21 yoy compared to 1H21 yoy (Fig 2); ii) the notable fall in mix of traditional protection products (Fig 5); iii) the fall in China VONB margins to an 8-year low (Fig 8).

Reiterate Add with lower TP of HK\$101; remains top sector pick

Our GGM-based TP dips to HK\$101 from HK\$107, driven by slow er FY22F VONB grow th due to HK's Covid-19 outbreak. Our 5.4-10.2% low er EPS over FY22F-24F is due to reduced premium grow th and investment income assumptions. Potential catalysts are higher bond yields and a marked fall in Covid-19 cases, which could lead investors to expect a reopening of the HK-mainland borders. Downside risks include currency volatility and a prolonged Covid-19 outbreak.

Financial Summary	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Gross Premium (US\$m)	39,852	42,746	42,261	43,463	44,962
Investment And Other Income (US\$m)					
Net Premium (US\$m)	33,666	34,770	34,376	35,353	36,572
Net Profit (US\$m)	5,779	7,427	6,204	7,885	8,666
Normalised EPS (US\$)	0.48	0.61	0.51	0.65	0.72
Normalised EPS Growth	(3.4%)	28.5%	(16.5%)	27.1%	9.9%
FD Normalised P/E (x)	20.65	16.08	19.25	15.15	13.78
P/NB (x)	19.58	13.79	11.46	7.87	4.91
DPS (US\$)	0.17	0.19	0.19	0.21	0.24
Dividend Yield	1.77%	1.90%	1.95%	2.16%	2.39%
P/EV (x)	1.83	1.64	1.52	1.39	1.26
P/BV (x)	1.89	1.97	1.85	1.71	1.57
ROE	9.8%	12.0%	9.9%	11.7%	11.9%
% Change In Normalised EPS Estimates			(10.2%)	(5.4%)	(5.8%)
Normalised EPS/consensus EPS (x)			0.84	0.96	0.89

SOURCES: CGS-CIMB RESEARCH, COMPANY REPORTS

Analyst(s)




Michael CHANG, CFA T (852) 2539 1323 E michael.chang@cgs-cimb.com



Ending an 11-year wait

Figure 1: Ke versusourf	·	of the FY21 re	esults and t	the variand	Figure 2: VONB g	grow th (actual e	exchangerat	e [AER] basi	s)	
(US\$ m)	FY21A	CGS-CIMB FY21F	FY21 % variance	4Q21 % variance	FY21 growth		FY20	1H21	2H21	FY21
VONB	3,366	3,261	3.2%	15%	22%	Hong Kong	-66%	2%	82%	37%
EV	72,987	68,908	5.9%	n.a.	12%	Thailand	-5%	57%	10%	30%
						Singapore	-6%	39%	-11%	8%
NPAT	7,427	5,844	27.1%	n.a.	29%	Malaysia	-14%	94%	-11%	27%
OPAT	6,409	6,444	-0.5%	n.a.	8%	China	-17%	24%	-1%	14%
DPS (HK\$)	1.46	1.47	-1.0%	n.a.	8%	Other markets	-4%	5%	-6%	-1%
						Subtotal	-31%	26%	11%	19%
ANP	5,647	5,637	0.2%	n.a.	8%	Total	-33%	29%	15%	22%
VONB margin	59.3%	57.4%	3.2%	n.a.	13%					
	SOURCES	CGS-CIMB RESE	ARCH ESTIMA	TES, COMPANY	REPORTS		SOURCES:	CGS-CIMB RESE	ARCH, COMPANY	(REPORTS








Figure 6: VONB margin movement				Figure 7: VONB composition of AIA Group						
	FY20	1H21	FY21		FY20	FY21	1H21	2H21		
Start of the period VONB margin	62.9%	54.4%	52.6%	Hong Kong	16%	26%	18%	21%		
Product mix	-5.8%	1.0%	2.0%	Thailand	16%	18%	15%	17%		
Geographic mix	-0.5%	0.1%	0.2%	Singapore	9%	11%	11%	10%		
Channel mix and others	0.5%	0.7%	0.3%	Malaysia	8%	8%	7%	8%		
Reduced acquisition and expense overruns	-2.5%	1.9%	1.3%	China	38%	22%	32%	31%		
Others including assumption changes	-2.0%	0.9%	2.9%	Other markets	13%	15%	17%	14%		
End of the period VONB margin	52.6%	59.0%	59.3%	Total	100%	100%	100%	100%		
SOURCES: CG	S-CIMB RESEARC	CH, COMPAN	Y REPORTS			SOURCES: (CGS-CIMB RESEARCH, COMPANY F	REPORTS		



Changes to our earnings, VONB and EVPS estimates

We cut our FY22F-24F EPS by 5.4% to 10.2%, mainly to reflect premium growth (primarily due to a worse-than-expected Covid-19 outbreak in Hong Kong) and lower investment income due to weak equity markets. Our FY22F-24F VONB estimates are cut by 1.2-1.3%, as we similarly reflect the adverse effects of a worse-than-expected Covid-19 outbreak in Hong Kong (Fig 10).

		FY22F			FY23F			FY24F	
(US\$ m)	Old	New	% chg	Old	New	% chg	Old	New	% chg
Net premiums, fee income & other oper. revenue	35,175	34,376	-2.3%	36,145	35,353	-2.2%	37,340	36,572	-2.1%
Investment income	12,287	11,553	-6.0%	13,366	12,567	-6.0%	14,605	13,732	-6.0%
Total Revenue	47,462	45,928	-3.2%	49,511	47,920	-3.2%	51,945	50,304	-3.2%
Total expenses	39,252	38,122	-2.9%	40,445	39,310	-2.8%	41,861	40,773	-2.6%
OPAT attrib. to shareholders of AIA Group	7,009	6,604	-5.8%	7,741	7,285	-5.9%	8,612	8,065	-6.3%
Non operating items	-100	-400	300.0%	600	600	0.0%	601	601	0.0%
NPAT attrib to shareholders of AIA Group	6,909	6,204	-10.2%	8,341	7,885	-5.4%	9,213	8,666	-5.9%
EPS (US\$)	0.57	0.51	-10.2%	0.69	0.65	-5.4%	0.76	0.72	-5.8%
DPS (US\$)	0.21	0.19	-6.2%	0.23	0.21	-6.3%	0.25	0.24	-6.8%
BVPS (US\$)	5.91	5.32	-9.9%	6.38	5.78	-9.5%	6.91	6.27	-9.2%
VONB per share (US\$)	0.30	0.29	-1.3%	0.35	0.35	-1.3%	0.42	0.42	-1.2%
EVPS (US\$)	6.19	6.51	5.2%	6.79	7.12	5.0%	7.47	7.82	4.7%
ROE (%)	10.0%	9.9%	0.0% pts	11.2%	11.7%	0.5% pts	11.4%	11.9%	0.4% pts
ROEV (%)	12.1%	11.0%	-1.0% pts	13.2%	12.5%	-0.7% pts	13.5%	12.8%	-0.7% pts



Valuation and recommendation

We cut our target price from HK\$107 to HK\$101. Our target price is based on a Gordon Growth Model (GGM)-derived P/EV multiple, which we apply to FY22F embedded value per share (EVPS) (unchanged).

We value AIA Group using GGM to derive a target P/EV multiple of 2.0x (previously 2.2x), assuming COE of 8.3% (unchanged), terminal growth rate of 4.8% (unchanged), as well as a sustainable return on embedded value (ROEV) of 11.9% (previously 12.7%), based on the average ROEV over FY20-24F.

We then apply this to our FY22F EVPS estimate of US\$6.51 (previously FY22F EVPS estimate of US\$6.19), after converting at an assumed exchange rate of US\$/HK\$ of 7.79 (unchanged), to arrive at our target price of HK\$101 (previously HK\$107) (Fig 11).

Old	New	% chg
8.3%	8.3%	0.0% pts
4.8%	4.8%	0.0% pts
12 7%	11.9%	-0.9% pts
2.2x	2.0x	-10.9%
6.19	6.51	5.2%
48.19	50.71	5.2%
7.79	7.79	0.0%
107.00	101.00	-5.6%
0.30	0.29	-1.3%
2.31	2.28	-1.3%
25.4x	22.0x	-13.4%
		77.25
		31%
	8.3% 4.8% 12.7% 2.2x 6.19 48.19 7.79 107.00 0.30 2.31	12.7% 11.9% 2.2x 2.0x 6.19 6.51 48.19 50.71 7.79 7.79 107.00 101.00 0.30 0.29 2.31 2.28

We show in Fig 12 our embedded value forecasts up to FY24F.



(US\$ m)	FY15	FY16	FY17	FY18	FY19	FY20	FY21F	FY22F	FY23F	FY24
Opening EV	37,153	38,198	42,114	50,779	54,517	61,985	65,247	72,987	78,764	86,20
Value of new business	2,198	2,750	3,512	3,955	4,154	2,765	3,366	3,548	4,223	5,06
Expected return on EV	2,698	2,854	3,317	3,893	4,105	4,176	4,402	4,846	5,293	5,82
Operating experience variance	274	365	385	612	600	533	451	396	345	29
Operating assumption changes	-26	29	-81	-9	34	16	-14	-7	-4	-2
Finance costs on medium term notes	-76	-111	-136	-173	-208	-247	-309	-340	-374	-41′
EV operating profit	5,068	5,887	6,997	8,278	8,685	7,243	7,896	8,443	9,483	10,779
Investment return variance	-1,804	-37	1,517	-2,218	517	-1,868	1,293	-719	188	196
Effect of change in economic assumptions	145	-236	-190	47	-254	-1,013	434	0	0	(
Other non operating variances	369	-22	-330	270	-78	-330	1,200	0	0	(
Total EV profit	3,778	5,592	7,994	6,377	8,870	4,032	10,823	7,724	9,671	10,975
Dividends	-814	-1,124	-1,376	-1,589	-1,961	-1,997	-2,147	-2,278	-2,396	-2,646
Other capital movements	-12	-5	134	-13	-111	63	-126	0	0	(
Effect of changes in exchange rates	-1,907	-547	1,265	-1,037	670	1,164	-810	332	166	83
Closing EV	38,198	42,114	50,131	54,517	61,985	65,247	72,987	78,764	86,204	94,616
Number of shares	12,048	12,056	12,074	12,077	12,089	12,095	12,097	12,099	12,101	12,103
EV per share	3.17	3.49	4.15	4.51	5.13	5.39	6.03	6.51	7.12	7.82

AIA currently trades at a forward P/EV premium over other HK insurers under our coverage (average of 0.4x for FY22F). We believe this is justified given its lower risk profile, superior management quality, and track record for delivering consistent shareholder returns. As such, we reiterate our Add rating.

	Ticker	Rec	Market Cap	Price	Target	+/-	I	P/EV (x))	VONE	s multip	ole (x)	I	P/BV (x))	Grou	p ROE\	/ (%)
			(US\$bn)	(Lcy)	Price (Lcy)	(%)	FY20A	FY21F	FY22F	FY20A	FY21F	FY22F	FY20A	FY21F	FY22F	FY20A	FY21F	FY22F
China Life	2628 HK	Add	129.97	12.08	19.20	59%	0.27x	0.24x	0.22x	-13.4x	-15.5x	-22.5x	0.6x	0.6x	0.5x	16.8	12.7	12.7
Ping An	2318 HK	Add	197.71	54.85	81.00	48%	0.60x	0.56x	0.52x	-14.3x	-19.6x	-22.0x	1.0x	0.9x	0.8x	5.0	5.6	11.1
CPIC	2601 HK	Add	46.09	20.45	29.70	45%	0.36x	0.33x	0.29x	-16.1x	-17.1x	-18.2x	0.7x	0.7x	0.7x	18.7	11.8	14.4
PICC P&C	2328 HK	Add	21.74	7.55	9.40	25%	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	0.7x	0.7x	0.6x	n.a.	n.a.	n.a.
AIA	1299 HK	Add	159.18	77.25	101.00	31%	1.84x	1.64x	1.52x	19.7x	13.9x	11.6x	1.9x	2.0x	1.9x	8.4	15.3	11.0
NCI	1336 HK	Add	20.50	21.65	33.10	53%	0.23x	0.21x	0.19x	-20.1x	-27.7x	-28.7x	0.6x	0.5x	0.5x	19.5	12.9	10.6
HK-listed v	weighted ave	erage					0.84x	0.76x	0.71x	-4.7x	-9.1x	-12.4x	1.1x	1.1x	1.0x	10.4	10.8	11.7
HK-listed v	weighted ave	erage ex	AIA				0.44x	0.41x	0.38x	-14.5x	-18.4x	-22.1x	0.8x	0.8x	0.7x	11.2	9.0	12.0

PIC: China Pacific Insurance Company, NCI: New China Life Insurance; PICC P&C: PICC (The People's Insurance Company of China) Property & Casualty

Potential re-rating catalysts are the announcement of an Insurance Connect (see The importance of being connected dated 10 Jul 2020), the announcement of a Greater Bay Area travel bubble (And so it begins, dated 19 Jun 2020), as well as the announcement of further regulatory approvals to expand into new regions in China (see New frontiers dated 2 Feb 2019). An earlier-than-expected peak of Covid-19 infections is another potential re-rating catalyst.



Figure 14: Key financial data							
(Yr-end 30 Nov for FY15-FY17/ Yr-end 31 Dec for FY18-19A and FY20F-FY21F)	2018A	2019A	2020A	2021A	2022F	2023F	2024F
Summary	2016A	2019A	2020A	2021A	20225	20235	20246
EPS (US\$)	0.26	0.50	0.48	0.62	0.51	0.65	0.72
Operating EPS (US\$)	0.20	0.30	0.40	0.53	0.55	0.60	0.67
P/E ratio (x) (oper. EPS)	21.1	21.1	20.2	18.8	18.2	16.5	14.9
EPS grow th (%)	-48.4%	88.7%	-3.5%	28.5%	-16.5%	27.1%	9.9%
DPS (US\$)	0.16	0.16	0.17	0.19	0.19	0.21	0.24
Dividend yield (%)	1.9%	1.5%	1.4%	1.9%	1.9%	2.1%	2.3%
Issued shares (m)	12,077	12,089	12,095	12,097	12,099	12,101	12,103
BVPS (US\$)	3.23	4.55	5.23	5.00	5.32	5.78	6.27
P/BV (x)	3.09	2.19	1.91	1.99	1.87	1.73	1.59
EV per share (US\$)	4.51	5.13	5.39	6.03	6.51	7.12	7.82
Grow th of EV per share	9%	14%	5%	12%	8%	9%	10%
ROEV	10.5%	17.5%	8.4%	15.3%	11.0%	12.5%	12.8%
Price/EV (x)	2.21	1.94	1.85	1.65	1.53	12.5%	12.0%
VONB per share (US\$)	0.34	0.34	0.23	0.28	0.29	0.35	0.42
Grow th of VONB per share	16%	2%	-33%	22%	5%	19%	20%
NB multiple	16.2	14.1	20.0	14.1	11.8	8.2	5.1
· · · · · · · · · · · · · · · · · · ·	10.2		20.0		0	5.2	0.1
Profit & Loss (US\$mn) Net premium	32,222	32,896	33,666	34,770	34,376	35 353	26 570
	-	-	-		,	35,353	36,572
Investment income Total Revenue	8,728 40,950	8,899 41,795	9,398 43,064	10,631 45,401	11,553 45,928	12,567 47,920	13,732 50,304
Insurance-related expenses	40,950 31,180	31,972	43,004 32,748	43,401 34,039	43,320 34,225	35,269	36,521
Other operating-related expenses	2,877	3,050	3,353	3,786	3,897	4,041	4,251
Underwriting income	6,893	6,773	6,963	7,576	7,806	8,610	9,531
Share of P/L from associates	0,000	(8)	(17)	(11)	(11)	(11)	(11)
Operating profit/(loss)	6,893	6,765	6,946	7,565	7,795	8,599	9,520
Operating profit after tax (OPAT)	5,731	5,734	5,986	6,455	6,652	7,337	8,123
OPAT attrib to shareholders of AIA Group	5,684	5,689	5,942	6,409	6,604	7,285	8,065
Non operating items	(2,521)	290	(163)	1,018	(400)	600	601
Net profit after tax	3,163	5,979	5,779	7,427	6,204	7,885	8,666
Balance sheet (US\$m)	2018A	2019A	2020A	2021A	2022F	2023F	2024F
Assets							
Investment assets (excluding unit linked)	171,337	212,742	247,408	253,585	275,850	301,419	329,359
Investment assets (including unit linked)	23,938	31,456	36,302	40,059	46,230	53,352	61,572
Other assets	34,531	39,934	42,411	46,230	48,677	50,995	53,181
Total assets	229,806	284,132	326,121	339,874	370,756	405,767	444,112
Liekilitiee							
Liabilities Insurance contract liabilities	164,764	192,181	223,071	000 400	264 660	004 404	205 076
Investment contract liabilities	7,885	192,181	12,881	239,423 11,860	261,660 12,448	284,131 13,064	305,976 13,711
Borrowings	4,954	5,757	8,559	9,588	12,440	21,192	31,507
Other liabilities	4,954	18,526	17,942	9,588 18,069	17,499	16,948	16,414
Total liabilities	190,400	228,737	262,453	278,940	305,861	335,336	367,608
Net assets	39,406	55,395	63,668	60,934	64,895	70,431	76,505
		·			·		
Equity attributable to shareholders	39,006	54,947	63,200	60,467	64,398	69,892	75,918
Ratio and growth analysis							
ROA	1.4%	2.3%	1.9%	2.2%	1.7%	2.0%	2.0%
ROE	7.8%	12.7%	9.8%	12.0%	9.9%	11.7%	11.9%
Payout ratio	60.0%	32.7%	36.4%	30.4%	37.6%	32.7%	32.9%
Grow th in net earned premium	25.3%	2.1%	2.3%	3.3%	-1.1%	2.8%	3.4%
Grow th in operating profit after tax & minorities	22.3%	0.1%	4.4%	7.9%	3.0%	10.3%	10.7%
Asset portfolio mix	100%	100%	100%	100%	100%	100%	100%
- Fixed interest assets	83%	82%	83%	80%	80%	80%	80%
 Equity securities & interest in investment funds 	11%	12%	13%	15%	15%	15%	15%
- Others	5%	5%	5%	5%	5%	5%	5%
Average investment income yield	5.4%	5.2%	4.4%	4.3%	4.6%	4.6%	4.6%
Insurance-related expense ratio	76.1%	76.5%	76.0%	75.0%	74.5%	73.6%	72.6%
Operating expense ratio	7.0%	7.3%	7.8%	8.3%	8.5%	8.4%	8.5%
Grow th of operating profit after tax and minorities	22.3%	0.1%	4.4%	7.9%	3.0%	10.3%	10.7%
Grow th of net profit after tax and minorities	-48.3%	89.0%	-3.3% SOURC	28.5%	-16.5%	27.1%	9.9%






AlA scored a B+ rating for its combined ESG score by Refinitiv in 2020. According to its 2021 ESG report, its MSCI ESG rating was AA in 2021 (2020: A; 2019: BBB). AlA's ambition is to be a global industry leader in ESG, shaping a sustainable future for the communities it serves, and creating long-term value for all its stakeholders. The company's ESG strategy is realised by improving healthcare standards and wellness levels, by green operations, driving sustainable investing, supporting people culture, and effective governance. AlA proactively encompasses green operations, including: 1) increased digitalisation and automation to reduce the use of paper and need for business travel; 2) reduced carbon footprint; and 3) ensuring that all new buildings adhere to industry-recognised green building standards. AlA states that it will continue to help its customers live healthier, longer and better lives, and by doing so, make a positive difference to the sustainable development of its business.

Keep your eye on	Implications
According to Bloomberg, environment groups SumOfUs and Insure Our Future have urged AIA to divest its assets in coal and join 65 industry peers that have done so. AIA, subsequently, in its 2020 ESG report pledged to divest and/or run off its entire directly-managed equity and fixed income exposure to coal mining and coal-fired power businesses and on 7 Dec 2021 announced that it has achieved this. AIA also stated that it would no longer make new investments in businesses involved directly in either mining coal or generating electricity from coal. It also announced on 7 Dec 2021 its commitment to achieve net- zero greenhouse gas emissions by 2050. It has also committed to the Science Based Targets Initiative (SBTi), a global body enabling businesses to set ambitious emissions reduction targets in line with the latest climate science.	We see this as a positive move which should catalyse a further improvement in AIA's ESG ratings and also valuation.
ESG highlights	Implications
According to AIA's 2021 ESG report, its Carbon Disclosure Project (CDP) score for climate change performance was B, down from A- in 2020. In the same report, AIA also stated that Sustainalytics has placed it in the second percentile of companies in the insurance industry for two years running and AIA received the 2022 Industry Top- Rated Badge as well as a brand new Regional Top-Rated Badge from Sustainalytics.	MSCI and Sustainalytics and we believe that such an excellent track record may not be adequately reflected in its valuation.
Trends	Implications
AlA's Refinitiv combined ESG score has been relatively stable over 2018-20 at B+, after rising from a B rating in 2017 and 2016. Its Refinitiv Environmental pillar score has risen to C+ in 2019 and 2020 from C over the 2016-18 period. Its Social pillar score has been constant at B over the 2016-20 period. Its Governance pillar score in 2020 is A+ and has remained at that level since 2019 (2018: A-; 2016 and 2017: B+). Its ESG controversies score has consistently ranked A+ over the 2016-20 period.	Given the higher ESG scores awarded by MSCI, CDP and Sustainalytics compared to Refinitiv, we see scope for AIA to improve its Refinitiv combined ESG score.
	SOURCES: CGS-CIMB RESEARCH, REFINITIV



BY THE NUMBERS



Profit & Loss

(US\$m)	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Revenue	33,666	34,770	34,376	35,353	36,572
Total Claims and Changes in Reserves	(32,748)	(34,039)	(34,225)	(35,269)	(36,521)
Acq. Costs/Other Underwriting Exp.					
Total Underwriting Result	(2,435)	(3,055)	(3,746)	(3,957)	(4,201)
Investment Income on Tech Reserve	0	0	0	0	0
Insurance Profit / (Loss)	(2,435)	(3,055)	(3,746)	(3,957)	(4,201)
Total Other Technical Income	(17)	(11)	(11)	(11)	(11)
Total Other Revenues	0	0	0	0	0
Total Operating Costs	0	0	0	0	0
Other Technical Income / (Loss)					
Depreciation And Amortisation	0	0	0	0	0
Operating Profit	(2,452)	(3,066)	(3,757)	(3,968)	(4,212)
Pretax Income/(Loss) from Assoc.	0	0	0	0	0
Post-Tax Oper. Earnings - Life/Other Biz					
Head Office Costs					
Non-Operating Income/(Expense)	0	0	0	0	0
Net Interest Income	0	0	0	0	0
Investment Income on Shareholders Fund	9,398	10,631	11,553	12,567	13,732
Other Income	(163)	1,018	(400)	600	601
Exceptional Items					
Pre-tax Profit	6,783	8,583	7,395	9,199	10,121
Taxation	(960)	(1,110)	(1,144)	(1,262)	(1,397)
Consolidation Adjustments & Others					
Exceptional Income - post-tax					
Profit After Tax	5,823	7,473	6,252	7,937	8,724
Minority Interests	(44)	(46)	(47)	(52)	(58)
Preferred Dividends					
Special Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Preference Dividends (Australia)					
Net Profit	5,779	7,427	6,204	7,885	8,666

Operating Ratios					
	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Premium Retention Ratio (life & Health)	84.5%	81.3%	81.3%	81.3%	81.3%
Benefits Ratio (life & Health)	(97.3%)	(97.9%)	(99.6%)	(99.8%)	(99.9%)
Acquisition Expense Ratio (life & Health)	0%	0%	0%	0%	0%
Admin Expense Ratio (life & Health)	0%	0%	0%	0%	0%
Total Expense Ratio (life & Health)	10.0%	10.9%	11.3%	11.4%	11.6%
Policyholder Dividends Ratio (life & Health)	0%	0%	0%	0%	0%
Combined Underwriting Ratio (life & Health)	(87.3%)	(87.0%)	(88.2%)	(88.3%)	(88.2%)
Underwriting Profit Margin (life & Health)	(7.2%)	(8.8%)	(10.9%)	(11.2%)	(11.5%)
Operating Profit Margin (life & Health)	(7.3%)	(8.8%)	(10.9%)	(11.2%)	(11.5%)

SOURCES: CGS-CIMB RESEARCH, COMPANY REPORTS



BY THE NUMBERS... cont'd

(US\$m)	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Fixed Assets					
Intangible Assets	0	0	0	0	0
Other Long Term Assets	326,121	339,874	370,756	405,767	444,112
Total Non-current Assets	326,121	339,874	370,756	405,767	444,112
Total Cash And Equivalents	0	0	0	0	0
Trade Debtors					
Other Current Assets	0	0	0	0	0
Total Current Assets	0	0	0	0	0
Creditors - Direct & Reinsurance Business					
Provision For Claims Outstanding	223,071	239,423	261,660	284,131	305,976
Other Current Liabilities	0	0	0	0	0
Total Current Liabilities	223,071	239,423	261,660	284,131	305,976
Total Long-term Debt	8,559	9,588	14,255	21,192	31,507
Hybrid Debt - Debt Component					
Other Liabilities	30,823	29,929	29,947	30,012	30,125
Total Non-current Liabilities	39,382	39,517	44,202	51,204	61,632
Total Technical & Other Provisions	0	0	0	0	0
Total Liabilities	262,453	278,940	305,861	335,336	367,608
Shareholders' Equity	63,200	60,467	64,398	69,892	75,918
Minority Interests	468	467	497	540	586
Total Equity	63,668	60,934	64,895	70,431	76,505
Life Embedded Value	65.247	72.987	78.764	86.204	94.616

Key Ratios					
	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
Net Premium Growth	2.34%	3.28%	(1.13%)	2.84%	3.45%
Operating Profit Growth (Life & Health)	14.9%	25.0%	22.5%	5.6%	6.1%
Value Of New Life Business Growth (after-tax)	(33.4%)	21.7%	5.4%	19.0%	20.0%
Life Embedded Value Growth	5.3%	11.9%	7.9%	9.4%	9.8%
Pre-tax Margin	20.1%	24.7%	21.5%	26.0%	27.7%
Net Profit Margin	17.2%	21.4%	18.0%	22.3%	23.7%
Effective Tax Rate	14.2%	12.9%	15.5%	13.7%	13.8%
Net Dividend Payout Ratio	36.4%	30.4%	37.6%	32.7%	32.9%
Return On Average Assets	1.91%	2.24%	1.76%	2.04%	2.05%
Net Gearing	11.9%	13.7%	18.1%	23.3%	29.3%
Financial Leverage	5.17	5.39	5.69	5.78	5.83
Equity / Assets	19.4%	17.8%	17.4%	17.2%	17.1%

Key Drivers					
	Dec-20A	Dec-21A	Dec-22F	Dec-23F	Dec-24F
VONB growth (%)	-33.4%	21.7%	5.4%	19.0%	20.0%
Embedded value growth (%)	5.3%	11.9%	7.9%	9.4%	9.8%
Insurance-related expenses / Net premiums & other	1.0	1.0	1.0	1.0	1.0
Operating-related expenses/ Total revenue (%)	7.8%	8.3%	8.3%	8.2%	8.2%
Effective tax rate (of operating profit only) (%)	13.8%	14.7%	14.7%	14.7%	14.7%
Dividend payout ratio (based on operating profits	0.4	0.4	0.4	0.4	0.4

SOURCES: CGS-CIMB RESEARCH, COMPANY REPORTS



DISCLAIMER

The content of this report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by and belongs to CGS-CIMB. Reports relating to a specific geographical area are produced and distributed by the corresponding CGS-CIMB entity as listed in the table below.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

By accepting this report, the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein (including the "Restrictions on Distributions" set out below). Any failure to comply with these limitations may constitute a violation of law. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CGS-CIMB.

The information contained in this research report is prepared from data believed to be correct and reliable at the time of issue of this report. CGS-CIMB may or may not issue regular reports on the subject matter of this report at any frequency and may œase to do so or change the periodicity of reports at any time. CGS-CIMB has no obligation to update this report in the event of a material change to the information contained in this report. CGS-CIMB does not accept any obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant, (ii) ensure that the content of this report constitutes all the information a prospective investor may require, (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, CGS-CIMB, its affiliates and related persons including China Galaxy International Financial Holdings Limited ("CGIFHL") and CIMB Group Sdn. Bhd. ("CIMBG") and their respective related corporations (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof. In particular, CGS-CIMB disclaims all responsibility and liability for the views and opinions set out in this report.

Unless otherwise specified, this report is based upon sources which CGS-CIMB considers to be reasonable. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research.

Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of CGS-CIMB or any of its affiliates (including CGIFHL, CIMBG and their respective related corporations) to any person to buy or sell any investments.

CGS-CIMB, its affiliates and related corporations (including CGIFHL, CIMBG and their respective related corporations) and/or their respective directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this research report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities. Further, CGS-CIMB, its affiliates and their respective related corporations (including CGIFHL, CIMBG and their respective related corporations) do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

CGS-CIMB or its affiliates (including CGIFHL, CIMBG and their respective related corporations) may enter into an agreement with the company(ies) covered in this report relating to the production of research reports. CGS-CIMB may disclose the contents of this report to the company(ies) covered by it and may have amended the contents of this report following such disclosure.

The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report. The analyst(s) who prepared this research report is prohibited from receiving any compensation, incentive or bonus based on specific investment banking transactions or for providing a specific recommendation for, or view of, a particular company. Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the research personnel involved in the preparation of this report may also participate in the solicitation of the businesses as described above. In reviewing this research report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

Reports relating to a specific geographical area are produced by the corresponding CGS-CIMB entity as listed in the table below. The term "CGS-CIMB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case except as otherwise stated herein, CGS-CIMB Securities International Pte. Ltd. and its affiliates, subsidiaries and related corporations.



Insurance - Life | Hong Kong AIA Group | March 14, 2022

Country	CGS-CIMB Entity	Regulated by
Hong Kong	CGS-CIMB Securities (Hong Kong) Limited	Securities and Futures Commission Hong Kong
India	CGS-CIMB Securities (India) Private Limited	Securities and Exchange Board of India (SEBI)
Indonesia	PT CGS-CIMB Sekuritas Indonesia	Financial Services Authority of Indonesia
Malaysia	CGS-CIMB Securities Sdn. Bhd.	Securities Commission Malay sia
Singapore	CGS-CIMB Securities (Singapore) Pte. Ltd.	Monetary Authority of Singapore
South Korea	CGS-CIMB Securities (Hong Kong) Limited, Korea Branch	Financial Services Commission and Financial Supervisory Service
Thailand	CGS-CIMB Securities (Thailand) Co. Ltd.	Securities and Exchange Commission Thailand

Other Significant Financial Interests:

(i) As of February 28, 2022 CGS-CIMB has a proprietary position in the securities (which may include but not be limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report.

(a) -

(ii) Analyst Disclosure: As of March 14, 2022, the analyst(s) who prepared this report, and the associate(s), has / have an interest in the securities (which may include but not be limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report:

(a) -

This report does not purport to contain all the information that a prospective investor may require. Neither CGS-CIMB nor any of its affiliates (including CGIFHL, CIMBG and their related corporations) make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report. Neither CGS-CIMB nor any of its affiliates nor their related persons (including CGIFHL, CIMBG and their related corporations) shall be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof. This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst CGS-CIMB's clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may

generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments or any derivative instrument, or any rights pertaining thereto.

Investors are advised to make their own independent evaluation of the information contained in this research report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this research report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

Restrictions on Distributions

Australia: Despite anything in this report to the contrary, this research is provided in Australia by CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited. This research is only available in Australia to persons who are "wholesale clients" (within the meaning of the Corporations Act 2001 (Cth) and is supplied solely for the use of such wholesale clients and shall not be distributed or passed on to any other person. You represent and warrant that if you are in Australia, you are a "wholesale client". This research is of a general nature only and has been prepared without taking into account the objectives, financial situation or needs of the individual recipient. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited do not hold, and are not required to hold an Australian financial services license. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited (Hong Kong) Limited rely on "passporting" exemptions for entities appropriately licensed by the Monetary Authority of Singapore (under ASIC Class Order 03/1102) and the Securities and Futures Commission in Hong Kong (under ASIC Class Order 03/1102).

Canada: This research report has not been prepared in accordance with the disclosure requirements of Dealer Member Rule 3400 – Research Restrictions and Disclosure Requirements of the Investment Industry Regulatory Organization of Canada. For any research report distributed by CIBC, further disclosures related to CIBC conflicts of interest can be found at https://researchcentral.cibcwm.com.

China: For the purpose of this report, the People's Republic of China ("PRC") does not include the Hong Kong Special Administrative Region, the Macau Special Administrative Region or Taiwan. The distributor of this report has not been approved or licensed by the China Securities Regulatory Commission or any other relevant regulatory authority or governmental agency in the PRC. This report contains only marketing information. The distribution of this report is not an offer to buy or sell to any person within or outside PRC or a solicitation to any person within or outside of PRC to buy or sell any instruments described herein. This report is being issued outside the PRC to a limited number of institutional investors and may not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose.

France: Only qualified investors within the meaning of French law shall have access to this report. This report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial instruments and it is not intended as a solicitation for the purchase of any financial instrument.

Germany: This report is only directed at persons who are professional investors as defined in sec 31a(2) of the German Securities Trading Act (WpHG). This publication constitutes research of a non-binding nature on the market situation and the investment instruments cited here at the time of the publication of the information.

The current prices/yields in this issue are based upon closing prices from Bloomberg as of the day preceding publication. Please note that neither the German Federal Financial Supervisory Agency (BaFin), nor any other supervisory authority exercises any control over the content of this report.

Hong Kong: This report is issued and distributed in Hong Kong by CGS-CIMB Securities (Hong Kong) Limited ("CHK") which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities) and Type 4 (advising on securities) activities. Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact the Head of Sales at CGS-CIMB Securities (Hong Kong) Limited. The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets



Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CHK has no obligation to update its opinion or the information in this research report.

This publication is strictly confidential and is for private circulation only to clients of CHK.

CHK does not make a market on other securities mentioned in the report

None of the analyst(s) or the associates serve as an officer of the listed corporation mentioned in this report.

CIMB does not have an officer serving in any of the listed corporation mentioned in this report

CIMB does not receive any compensation or other benefits from any of the listed corporation mentioned, relating to the production of research reports.

India: This report is issued and distributed in India by CGS-CIMB Securities (India) Private Limited ("CGS-CIMB India"). CGS-CIMB India is a subsidiary of CGS-CIMB Securities International Pte. Ltd. which is in turn is a 50:50 joint venture company of CGIFHL and CIMBG. The details of the of CGS-CIMB members of the group of companies can be found at www.cgs-cimb.com, CGIFHL at www.chinastock.com.hk/en/ACG/ContactUs/index.aspx and CIMBG at www.cimb.com/en/who-we-are.html. CGS-CIMB India is registered with the National Stock Exchange of India Limited and BSE Limited as a trading and clearing member (Merchant Banking Number: INM000012037) under the Securities and Exchange Board of India (Stock Brokers and Sub-Brokers) Regulations, 1992. In accordance with the provisions of Regulation 4(g) of the Securities and Exchange Board of India (Investment Advisers) Regulations, 2013, CGS-CIMB India is not required to seek registration with the Securities and Exchange Board of India ("SEBI") as an Investment Adviser. CGS-CIMB India is registered with SEBI (SEBI Registration Number: INZ000209135) as a Research Analyst (INH00000669) pursuant to the SEBI (Research Analysts) Regulations, 2014 ("Regulations").

This report does not take into account the particular investment objectives, financial situations, or needs of the recipients. It is not intended for and does not deal with prohibitions on investment due to law/jurisdiction issues etc. which may exist for certain persons/entities. Recipients should rely on their own investigations and take their own professional advice before investment.

The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of CGS-CIMB India and they have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues, client feedback and competitive factors. Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed or proposed to be performed by CGS-CIMB India or its affiliates.

CGS-CIMB India does not have actual / beneficial ownership of 1% or more securities of the subject company in this research report, at the end of the month immediately preceding the date of publication of this research report. However, since affiliates of CGS-CIMB India are engaged in the financial services business, they might have in their normal course of business financial interests or actual / beneficial ownership of one per cent or more in various companies including the subject company in this research report.

CGS-CIMB India or its associates, may: (a) from time to time, have long or short position in, and buy or sell the securities of the subject company in this research report; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company in this research report or act as an advisor or lender/borrower to such company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

CGS-CIMB India, its associates and the analyst engaged in preparation of this research report have not received any compensation for investment banking, merchantbanking or brokerage services from the subject company mentioned in the research report in the past 12 months.

CGS-CIMB India, its associates and the analyst engaged in preparation of this research report have not managed or co-managed public offering of securities for the subject company mentioned in the research report in the past 12 months. The analyst from CGS-CIMB India engaged in preparation of this research report or his/her relative (a) do not have any financial interests in the subject company mentioned in this research report; (b) do not own 1% or more of the equity securities of the subject company mentioned in the received any material conflict of interest at the time of publication of the research report.

Indonesia: This report is issued and distributed by PT CGS-CIMB Sekuritas Indonesia ("CGS-CIMB Indonesia"). The views and opinions in this research report are our own as of the date hereof and are subject to change. CGS-CIMB Indonesia has no obligation to update its opinion or the information in this research report. This report is for private circulation only to clients of CGS-CIMB Indonesia. Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable Indonesian capital market laws and regulations.

This research report is not an offer of securities in Indonesia. The securities referred to in this research report have not been registered with the Financial Services Authority (Otoritas Jasa Keuangan) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market law and regulations.

Ireland: CGS-CIMB is not an investment firm authorised in the Republic of Ireland and no part of this document should be construed as CGS-CIMB acting as, or otherwise claiming or representing to be, an investment firm authorised in the Republic of Ireland.

Malaysia: This report is distributed in Malaysia by CGS-CIMB Securities Sdn. Bhd. ("CGS-CIMB Malaysia") solely for the benefit of and for the exclusive use of our clients. Recipients of this report are to contact CGS-CIMB Malaysia, at Level 29, Menara Bumiputra-Commerce, No. 11, Jalan Raja Laut, 50350 Kuala Lumpur, Malaysia, in respect of any matters arising from or in connection with this report. CGS-CIMB Malaysia has no obligation to update, revise or reaffirm its opinion or the information in this research reports after the date of this report.

New Zealand: In New Zealand, this report is for distribution only to persons who are wholesale clients pursuant to section 5C of the Financial Advisers Act 2008.

Singapore: This report is issued and distributed by CGS-CIMB Securities (Singapore) Pte Ltd ("CGS-CIMB Singapore"). CGS-CIMB Singapore is a capital markets services licensee under the Securities and Futures Act (Chapter 289). Accordingly, it is exempted from the requirement to hold a



financial adviser's licence under the Financial Advisers Act, Cap 110 ("FAA") for advising on investment products, by issuing or promulgating research analyses or research reports, whether in electronic, print or other form. CGS-CIMB Singapore is subject to the applicable rules under the FAA unless it is able to avail itself to any prescribed exemptions.

Recipients of this report are to contact CGS-CIMB Singapore, 10 Marina Boulevard, Marina Bay Financial Centre Tower 2, #09-01, Singapore 018983 in respect of any matters arising from, or in connection with this report CGS-CIMB Singapore has no obligation to update its opinion or the information in this research report. This publication is strictly confidential and is for private circulation only. If you have not been sent this report by CGS-CIMB Singapore directly, you may not rely, use or disclose to anyone else this report or its contents.

If the recipient of this research report is not an accredited investor, expert investor or institutional investor, CGS-CIMB Singapore accepts legal responsibility for the contents of the report without any disclaimer limiting or otherwise curtailing such legal responsibility. If the recipient is an accredited investor, expert investor or institutional investor, the recipient is deemed to acknowledge that CGS-CIMB Singapore is exempt from certain requirements under the FAA and its attendant regulations, and as such, is exempt from complying with the following:

(a) Section 25 of the FAA (obligation to disclose product information);

(b) Section 27 (duty not to make recommendation with respect to any investment product without having a reasonable basis where you may be reasonably expected to rely on the recommendation) of the FAA;

- (c) MAS Notice on Information to Clients and Product Information Disclosure [Notice No. FAA-N03];
- (d) MAS Notice on Recommendation on Investment Products [Notice No. FAA-N16];
- (e) Section 36 (obligation on disclosure of interest in specified products), and

(f) any other laws, regulations, notices, directive, guidelines, circulars and practice notes which are relates to the above, to the extent permitted by applicable laws, as may be amended from time to time, and any other laws, regulations, notices, directive, guidelines, circulars, and practice notes as we may notify you from time to time. In addition, the recipient who is an accredited investor, expert investor or institutional investor acknowledges that as CGS-CIMB Singapore is exempt from Section 27 of the FAA, the recipient will also not be able to file a civil claim against CGS-CIMB Singapore for any loss or damage arising from the recipient's reliance on any recommendation made by CGS-CIMB Singapore which would otherwise be a right that is available to the recipient under Section 27 of the FAA.

CGS-CIMB Singapore, its affiliates and related corporations, their directors, associates, connected parties and/or employees may own or have positions in specified products of the company(ies) covered in this research report or any specified products related thereto and may from time to time add to or dispose of, or may be materially interested in, any such specified products. Further, CGS-CIMB Singapore, its affiliates and its related corporations do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in specified products of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

As of March 11, 2022, CGS-CIMB Singapore does not have a proprietary position in the recommended specified products in this report.

CGS-CIMB Singapore does not make a market on the securities mentioned in the report.

South Korea: This report is issued and distributed in South Korea by CGS-CIMB Securities (Hong Kong) Limited, Korea Branch ("CGS-CIMB Korea") which is licensed as a cash equity broker, and regulated by the Financial Services Commission and Financial Supervisory Service of Korea. In South Korea, this report is for distribution only to professional investors under Article 9(5) of the Financial Investment Services and Capital Market Act of Korea ("FSCMA").

Spain: This document is a research report and it is addressed to institutional investors only. The research report is of a general nature and not personalised and does not constitute investment advice so, as the case may be, the recipient must seek proper advice before adopting any investment decision. This document does not constitute a public offering of securities.

CGS-CIMB is not registered with the Spanish Comision Nacional del Mercado de Valores to provide investment services.

Sweden: This report contains only marketing information and has not been approved by the Swedish Financial Supervisory Authority. The distribution of this report is not an offer to sell to any person in Sweden or a solicitation to any person in Sweden to buy any instruments described herein and may not be forwarded to the public in Sweden.

Switzerland: This report has not been prepared in accordance with the recognized self-regulatory minimal standards for research reports of banks issued by the Swiss Bankers' Association (Directives on the Independence of Financial Research).

Thailand: This report is issued and distributed by CGS-CIMB Securities (Thailand) Co. Ltd. ("CGS-CIMB Thailand") based upon sources believed to be reliable (but their accuracy, completeness or correctness is not guaranteed). The statements or expressions of opinion herein were arrived at after due and careful consideration for use as information for investment. Such opinions are subject to change without notice and CGS-CIMB Thailand has no obligation to update its opinion or the information in this research report.

CGS-CIMB Thailand may act or acts as Market Maker, and issuer and offeror of Derivative Warrants and Structured Note which may have the following securities as its underlying securities. Investors should carefully read and study the details of the derivative warrants in the prospectus before making investment decisions.

AAV, ACE, ADVANC, AEONTS, AMATA, AOT, AP, BAM, BANPU, BBL, BCH, BCP, BCPG, BDMS, BEC, BEM, BGRIM, BH, BJC, BTŠ, CBG, CENTEL, CHG, CK, CKP, COM7, CPALL, CPF, CPN, CRC, DELTA, DOHOME, DTAC, EA, EGCO, ESSO, GLOBAL, GPSC, GULF, GUNKUL, HANA, HMPRO, ICHI, INTUCH, IRPC, IVL, JAS, JMART, JMT, KBANK, KCE, KKP, KTB, KTC, LH, MAJOR, MEGA, MINT, MTC, NRF, OR, ORI, OSP, PLANB, PRM, PSL, PTG, PTL, PTT, PTTEP, PTTGC, QH, RATCH, RBF, RS, SAWAD, SCB, SCC, SCGP, SINGER, SPALI, SPRC, STA, STEC, STGT, SUPER, SYNEX, TASCO, TCAP, THANI, TIS CO, TKN, TOP, TQM, TRUE, TTB, TU, TVO, VGI, WHA

Corporate Governance Report:

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. CGS-CIMB Thailand does not confirm nor certify the accuracy of such survey result.



Insurance - Life | Hong Kong AIA Group | March 14, 2022

Score Range:	90 - 100	80 – 89	70 - 79	Below 70	No Survey Result
Description:	Excellent	Very Good	Good	N/A	N/A

United Arab Emirates: The distributor of this report has not been approved or licensed by the UAE Central Bank or any other relevant licensing authorities or governmental agencies in the United Arab Emirates. This report is strictly private and confidential and has not been reviewed by, deposited or registered with UAE Central Bank or any other licensing authority or governmental agencies in the United Arab Emirates. This report is being issued outside the United Arab Emirates to a limited number of institutional investors and must not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose. Further, the information contained in this report is not intended to lead to the sale of investments under any subscription agreement or the conclusion of any other contract of whatsoever nature within the territory of the United Arab Emirates.

United Kingdom and European Economic Area (EEA): In the United Kingdom and European Economic Area, this material is also being distributed by CGS-CIMB Securities (UK) Limited ("CGS-CIMB UK"). CGS-CIMB UK is authorized and regulated by the Financial Conduct Authority and its registered office is at 53 New Broad Street, London EC2M 1JJ. The material distributed by CGS-CIMB UK has been prepared in accordance with CGS-CIMB's policies for managing conflicts of interest arising as a result of publication and distribution of this material. This material is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of CGS-CIMB UK; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (c) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order; (d) are outside the United Kingdom subject to relevant regulation in each jurisdiction, material(all such persons together being referred to as "relevant persons"). This material is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

This material is categorised as non-independent for the purposes of CGS-CIMB UK and therefore does not provide an impartial or objective assessment of the subject matter and does not constitute independent research. Consequently, this material has not been prepared in accordance with legal requirements designed to promote the independence of research and will not be subject to any prohibition on dealing ahead of the dissemination of research. Therefore, this material is considered a marketing communication.

United States: This research report is distributed in the United States of America by CGS-CIMB Securities (USA) Inc, a U.S. registered brokerdealer and an affiliate of CGS-CIMB Securities Sdn. Bhd., CGS-CIMB Securities (Singapore) Pte Ltd, PT CGS-CIMB Sekuritas Indonesia, CGS-CIMB Securities (Thailand) Co. Ltd, CGS-CIMB Securities (Hong Kong) Limited and CGS-CIMB Securities (India) Private Limited, and is distributed solely to persons who qualify as "U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934. This communication is only for Institutional Investors whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed here in. CGS-CIMB Securities (USA) Inc, is a FINRA/SIPC member and takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc.

CGS-CIMB Securities (USA) Inc. does not make a market on other securities mentioned in the report.

CGS-CIMB Securities (USA) Inc. has not managed or co-managed a public offering of any of the securities mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. has not received compensation for investment banking services from any of the company mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. neither expects to receive nor intends to seek compensation for investment banking services from any of the company mentioned within the next 3 months.


United States Third-Party Disclaimer. If this report is distributed in the United States of America by Raymond James & Associates, Inc ("RJA"), this report is third-party research prepared for and distributed in the United States of America by RJA pursuant to an arrangement between RJA and CGS-CIMB Securities International Pte. Ltd. ("CGS-CIMB"). CGS-CIMB is not an affiliate of RJA. This report is distributed solely to persons who qualify as "U.S. Institutional Investors" or as "Major U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934, as amended. This communication is only for U.S. Institutional Investors or Major U.S. Institutional Investor whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major U.S. Institutional Investor must not rely on this communication. The delivery of this report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. If you are receiving this report in the U.S from RJA, a FINRA/SIPC member, it takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc. or RJA. https://raymondjames.com/InternationalEquityDisclosures

Other jurisdictions: In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is only for distribution to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Distribution of stock ratings and investment banking clients for quarter ended on 31 December 2021				
619 companies under coverage for quarter ended on 31 December 2021				
	Rating Distribution (%)	Investment Banking clients (%)		
Add	71.1%	1.5%		
Hold	21.8%	0.0%		
Reduce	7.1%	0.0%		



Spitzer Chart for stock being researched (2 year data)



Corporate Governance Report of Thai Listed Companies (CGR). CG Rating by the Thai Institute of Directors Association (Thai IOD) in 2021, Anti-Corruption 2021

ADVANC - Excellent, Certified, AMATA - Excellent, Certified, ANAN - Excellent, n/a, AOT - Excellent, n/a, AP - Excellent, Certified, ASP -Excellent, n/a, AWC - Excellent, Declared, AU - Good, n/a, BAM - Very Good, Certified, BAY - Excellent, Certified, BBL - Excellent, Certified, BCH - Very Good, Certified, BCP - Excellent, Certified, BCPG - Excellent, Certified, BDMS - Excellent, n/a, BEAUTY - Good, n/a, BEM -Excellent, n/a BH - Good, n/a, BJC - Very Good, n/a, BLA - Very Good, Certified, BTS - Excellent, Certified, CBG - Very Good, n/a, CCET - n/a, n/a, CENTEL - Excellent, Certified, CHAYO - Very Good, n/a, CHG - Very Good, n/a, CK - Excellent, n/a, COM7 - Excellent, Certified, CPALL -Excellent, Certified, CPF - Excellent, Certified, CPN - Excellent, Certified, CPNREIT - n/a, n/a, CRC - Excellent, Declared, DELTA - Excellent, Certified, DDD - Excellent, n/a, DIF - n/a, n/a, DOHOME - Very Good, Declared, DREIT - n/a, n/a, DTAC - Excellent, Certified, ECL - Excellent, Certified, EGCO - Excellent, Certified, EPG - Excellent, Certified, ERW - Very Good, Certified, GFPT - Excellent, Certified, GGC - Excellent, Certified, GLOBAL - Excellent, n/a, HANA - Excellent, Certified, HMPRO - Excellent, Certified, HUMAN - Good, n/a, ICHI - Excellent, Certified, III - Excellent Declared, INTUCH - Excellent, Certified, IRPC - Excellent, Certified, ITD - Very Good, n/a, IVL - Excellent, Certified, JASIF - n/a, n/a, JKN - n/a, Certified, JMT - Very Good, n/a, KBANK - Excellent, Certified, KCE - Excellent, Certified, KEX - Very Good, Declared, KKP - Excellent, Certified, KSL - Excellent, Certified, KTB - Excellent, Certified, KTC - Excellent, Certified, LH - Excellent, n/a, LPN - Excellent, Certified, M - Very Good, Certified, MAKRO - Excellent, Certified, MC - Excellent, Certified, MEGA - Very Good, n/a, MINT - Excellent, Certified, MTC - Excellent, Certified, NETBAY - Very Good, n/a, NRF - Very Good, Declared, OR - Excellent, n/a, ORI - Excellent, Certified, OSP - Excellent, n/a, PLANB -Excellent, Certified, PRINC - Very Good, Certified, PR9 - Excellent, Declared, PSH - Excellent, Certified, PTT - Excellent, Certified, PTTEP -Excellent. n/a. PTTGC - Excellent, Certified, QH - Excellent, Certified, RAM - n/a, n/a, RBF - Very Good, n/a, RS - Excellent, Declared, RSP -Good, n/a, S - Excellent, n/a, SAK - Very Good, Declared, SAPPE - Very Good, Certified, SAWAD - Very Good, n/a, SCB - Excellent, Certified, SCC - Excellent, Certified, SCGP - Excellent, Declared, SECURE - n/a, n/a, SHR - Excellent, n/a, SIRI - Excellent, Certified, SPA - Very Good, n/a, SPALI - Excellent, Certified, SPRC - Excellent, Certified, SSP - Good, Certified, STEC - Excellent, n/a, SVI - Excellent, Certified, SYNEX -Very Good, Certified, TCAP - Excellent, Certified, THANI - Excellent, Certified, TIDLOR - n/a, Certified TISCO - Excellent, Certified, TKN - Very Good, n/a, TOP - Excellent, Certified, TRUE - Excellent, Certified, TTB - Excellent, Certified, TU - Excellent, Certified, TVO - Excellent, Certified, VGI - Excellent Certified, WHA - Excellent Certified, WHART - n/a, n/a, WICE - Excellent Certified, WORK - Good, n/a, - CG Score 2021 from Thai Institute of Directors Association (IOD)

- Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of August 5, 2021) are categorised into: companies that have declared their intention to join CAC, and companies certified by CAC.

Recommendation	Framework
Stock Ratings	Definition:
Add	The stock's total return is expected to exceed 10% over the next 12 months.
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.
	turn of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net stock. Stock price targets have an investment horizon of 12 months.
Sector Ratings	Definition:
Ov erw eight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underw eight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.
Country Ratings	Definition:
Ov erw eight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underw eight	An Underweight rating means investors should be positioned with a below -market weight in this country relative to benchmark.

